KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash & Equivalents (2016 - 2025)

Regeneron Pharmaceuticals has reported Cash & Equivalents over the past 17 years, most recently at $3.1 billion for Q4 2025.

  • Quarterly results put Cash & Equivalents at $3.1 billion for Q4 2025, up 25.32% from a year ago — trailing twelve months through Dec 2025 was $3.1 billion (up 25.32% YoY), and the annual figure for FY2025 was $3.1 billion, up 25.32%.
  • Cash & Equivalents for Q4 2025 was $3.1 billion at Regeneron Pharmaceuticals, up from $2.5 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for REGN hit a ceiling of $3.9 billion in Q1 2023 and a floor of $1.4 billion in Q1 2021.
  • Median Cash & Equivalents over the past 5 years was $2.7 billion (2023), compared with a mean of $2.7 billion.
  • Biggest five-year swings in Cash & Equivalents: surged 132.68% in 2022 and later plummeted 42.94% in 2023.
  • Regeneron Pharmaceuticals' Cash & Equivalents stood at $2.9 billion in 2021, then increased by 7.63% to $3.1 billion in 2022, then dropped by 12.1% to $2.7 billion in 2023, then decreased by 8.86% to $2.5 billion in 2024, then rose by 25.32% to $3.1 billion in 2025.
  • The last three reported values for Cash & Equivalents were $3.1 billion (Q4 2025), $2.5 billion (Q3 2025), and $2.0 billion (Q2 2025) per Business Quant data.